Publications

Virtual Screening Identifies Inhibitors and First-in-Class Activators of 17β-Hydroxysteroid Dehydrogenase Type 10

ChemRxiv (2026). DOI: 10.26434/chemrxiv.15000304/v1

Tau aggregation induces cell death in iPSC-derived neurons

Aging Brain (2025), (Vol. 7) DOI: 10.1016/j.nbas.2025.100136.

Novel cell-based assay enables FRET based measurements of the dimerization activity of the chaperone DNAJB6

Biology Methods and Protocols (2026). DOI: 10.1093/biomethods/bpag005/8460761

Selective peroxynitrite-mediated protein nitration catalyzed by glyoxalase domain containing protein 4

PNAS (2026), Vol. 123 (6). DOI: 10.1073/pnas.2515002123

Analysis of amyloid beta oligomers by cyclic ion mobility-mass spectrometry

Anal Bioanal Chem (2026). DOI: 10.1007/s00216-026-06349-w

Visualizing and mapping Aβ plaques by curcumin-derived NIR sensors: Multitarget theranostic agents for Alzheimer's disease

Bioorganic Chemistry (2026) , (Vol. 171). DOI: 10.1016/j.bioorg.2026.109559.

Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies

Alzheimer’s disease-linked ACE variants increase ACE1 catalytic activity and production of angiotensin II

Journal of Biological Chemistry, (2026), (111171). DOI: 10.1016/j.jbc.2026.111171.

Structure and Dynamics of Lipid-Stabilized Amyloid Beta Aβ1–42 Oligomers

Aggregate (Vol 7, 1), (2026). DOI: 10.1002/agt2.70266

Systematic discovery of disease-modifying targets by prediction from knowledge graph-based AI model and experimental validation: Parkinson’s disease case

Computational and Structural Biotechnology Journal (2026). DOI: 10.1016/j.csbj.2025.12.035.

PAK1 inhibitor NVS‐PAK1‐1 preserves dendritic spines in amyloid/tau exposed neurons and 5xFAD mice

Alzheimer’s Dementia (2025) Dec;21(12). DOI: 10.1002/alz.71033

Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs

Stem Cell Reports (2019), (Vol. 13 j 684–699). DOI: 10.1016/j.stemcr.2019.08.011

Synthesis and evaluation of symmetric (1,4-diazepane-1,4-diyl)bis(phenylmethanone) derivatives as amyloid-beta aggregation inhibitors

Med Chem Res (2025). DOI: 10.1007/s00044-025-03512-3

Relationship between efficacy and preferential targeting of soluble Aβ aggregates

Alzheimer’s Association (2025), (Vol 11, Issue 4). DOI: 10.1002/trc2.70184

Protocol for in vitro phagocytosis assay for primary mouse microglia and human embryonic stem cell-derived microglia

STAR Protocols (2025), (Vol 6, Issue 4). DOI: 10.1016/j.xpro.2025.104219.

The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia

Nat Neurosci (2025). DOI: 10.1038/s41593-025-02125-8

Targeting of amyloid peptide fibers, a biomarker of Alzheimer’s disease, by designing specifically functionalized Iron Oxide Nanoparticles

HAL. (2025), 8 (43), pp.20822-20834. DOI:10.1021/acsanm.5c03459

Role of P-glycoprotein in attenuation of retinal amyloid-β peptide (1–40) clearance across the rat inner blood-retinal barrier induced by lipopolysaccharide

Science Direct (2025), 262. DOI: 10.1016/j.exer.2025.110759.

Peptidomimetics Based on C-Terminus of Blm10 Stimulate Human 20S Proteasome Activity and Promote Degradation of Proteins

Biomolecules (2022), 12, 777.  DOI: 10.3390/biom12060777

Detection of extracellular amyloid beta aggregates by an Aducanumab-based synNotch receptor: an in vitro proof-of-concept study

J Transl Med 23, 1255 (2025). DOI: 10.1186/s12967-025-07324-2